Clinical Trial

Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 3, 2025 (before its estimated June 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of 2 dose levels of TLC-2716 in subjects with hypertriglyceridemia and nonalcoholic fatty liver disease as assessed by changes in fasting triglycerides, liver steatosis by MRI, and other biomarkers.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-08-19.
Trial Details
NCT Number NCT06564584
Lead Sponsor OrsoBio, Inc
Conditions Hypertriglyceridemia, Nonalcoholic Fatty Liver Disease
Enrollment 30 participants
Start Date 2024-08-12
Primary Completion 2025-06 (estimated)
Study Completion 2025-09 (estimated)
Updated on ClinicalTrials.gov 2025-04-03